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Abstract
Purpose: The aim of this work was to develop a CAIX-specific nanobody conjugated to
IRDye800CW for molecular imaging of pre-invasive breast cancer.
Procedures: CAIX-specific nanobodies were selected using a modified phage display
technology, conjugated site-specifically to IRDye800CW and evaluated in a xenograft breast
cancer mouse model using ductal carcinoma in situ cells (DCIS).
Results: Specific anti-CAIX nanobodies were obtained. Administration of a CAIX-specific
nanobody into mice with DCIS xenografts overexpressing CAIX showed after 2 h a mean
tumor-to-normal tissue ratio (TNR) of 4.3±0.6, compared to a TNR of 1.4±0.2 in mice injected
with the negative control nanobody R2-IR. In DCIS mice, a TNR of 1.8±0.1 was obtained.
Biodistribution studies demonstrated an uptake of 14.0±1.1 %I.D./g in DCIS+CAIX tumors, 4.6±
0.8 %I.D./g in DCIS tumors, while 2.0±0.2 %I.D./g was obtained with R2-IR.
Conclusions: These results demonstrate the successful generation of a CAIX-specific nanobody-
IRDye800CW conjugate that can be used for rapid imaging of (pre-)invasive breast cancer.
Key words: Carbonic anhydrase IX, Nanobody, VHH, Optical imaging, Molecular fluorescence
pathology, Breast cancer
Introduction
Molecular imaging modalities such as positron emission
tomography (PET), single photon emission computed to-
mography (SPECT), and optical imaging use antibodies or
antibody-fragments to specifically track molecules or cells
[1]. The use of a targeting moiety, specific to antigens
present on tumor cells, results in higher contrast images
compared to imaging strategies with non-targeted contrast
agents [2–6]. Molecular imaging with fluorescent tracers
(optical molecular imaging) has recently gained more
interest [7–9], since it does not require expensive imaging
equipment or protective measures due to the absence of
ionizing radiation. As a result of the limited penetration of
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light into tissue, optical imaging is especially suitable for
imaging of superficial tumors, such as head and neck cancer
[10]. Moreover, optical imaging can be of help during tumor
resection and could reduce unneeded surgical procedures. In
addition, optical imaging is suitable for characterization of
histological biopsies and/or surgical specimens, an approach
we previously indicated as molecular fluorescence pathology
[11].
Hypoxia is a condition that is present in the majority of
solid tumors and normally absent in healthy tissue [12–14].
Several studies have demonstrated molecular imaging with
radiolabeled hypoxia-specific probes, such as 2-
nitroimidazoles, [18F]fluoromisonidazole, and Copper(II)-
d i A c e t y l - b i s (N 4 -m e t h y l T h i o S e -M i c a r b a z o n e )
([62Cu]ATSM) [15, 16]. These studies showed only moder-
ate tumor contrast mainly because of non-specific probe
uptake. Higher tumor-specificity might be obtained by
directly targeting proteins that are upregulated under
hypoxic conditions, such as carbonic anhydrase IX
(CAIX). CAIX expression is under control of hypoxia-
inducible factor 1α (HIF-1α), a transcription factor that is
stabilized under hypoxic conditions [17, 18]. We selected
CAIX as target for molecular imaging, as it is one of the
most tumor-specific membrane-bound proteins expressed in
hypoxic tumors. Although CAIX expression might not
reflect acute hypoxia because of a half-life of a few days,
it is a marker of chronic hypoxia in tumors. CAIX can
therefore be considered as a suitable marker that can be used
to discriminate cancer from non-cancerous tissues [19–21].
In a previous study, we presented the successful optical
imaging of pre-invasive cancer of the breast (ductal
carcinoma in situ, DCIS) with a CAIX-specific conventional
antibody (MabCAIX) [11]. Slow clearance of the antibody
resulted in suboptimal contrast during the first 24 h post
injection, and optimal tumor-to-normal tissue ratios (TNR)
were obtained 72 h after probe administration. More rapid
imaging would result in lower costs as less logistical
procedures are needed, and it would be more convenient
for the patient and healthcare workers. Faster clearance and
subsequent faster image acquisition with higher contrast can
be obtained using probes with molecular sizes that are below
the renal glomerular filtration threshold of about 50 kDa, as
recently demonstrated for the CAIX-specific tracer HS680,
which consists of a CAIX inhibitor conjugated to the
fluorescent dye Vivotag680 [22].
Promising probes for rapid molecular imaging are nano-
bodies or VHHs (variable domain of heavy chain anti-
bodies), which are antibody-fragments derived from heavy
chain antibodies that naturally occur in camelids [23].
Compared to conventional antibodies, nanobodies possess
several advantageous properties. Firstly, the molecular
weight of nanobodies is ten times lower (15 kDa vs.
150 kDa), which results in rapid tumor accumulation while
having short elimination half-life in the bloodstream, which
together lead to good contrast at early time points after
administration [24]. Secondly, nanobodies can be selected to
bind with high affinity to their target, and this high affinity is
essential for accumulation in the tumor [24]. Thirdly,
nanobodies can easily be produced in different organisms
such as bacteria, yeast and mammalian cells, and they are
more stable than other antibody-fragments [25]. Finally,
nanobodies are, thus far, known to be non-immunogenic
[25]. We and others have previously shown that nano-
bodies can successfully be used for rapid molecular
imaging of both epidermal growth factor receptor (EGFR)
and human epidermal growth factor receptor 2 (HER2) [9,
24, 26, 27].
In the current study, we present phage display selections
for nanobodies that specifically bind to the ectodomain of
CAIX. CAIX-specific nanobodies were selected from a
library derived from llamas immunized with hypoxic HeLa
cells. A second-generation library was produced on basis of
polymerase chain reaction (PCR) using complementarity
determining region 3 (CDR3) sequences from two initial
anti-CAIX nanobodies, and from this library, high-affinity
binders with specificity for CAIX were obtained. To avoid
affinity loss because of random conjugation, the nanobodies
were site-directedly conjugated to IRDye800CW and eval-
uated by optical molecular imaging of CAIX overexpressing
or endogenously expressing tumors in an orthotopic mouse
model of DCIS. Our data supports application of anti-CAIX
nanobodies for pre-, intra-, and postoperative optical
imaging of (pre-invasive) breast cancer and holds promise




Maxisorp plates were coated with 1.00, 0.50, 0.10, 0.05, and
0.00 μg recombinant CAIX (R&D systems, Minneapolis, USA).
Phages were produced from E.coli TG1 harboring the library after
infection with helper phage VSCM13 (Strategene, Agilent
Technologies Netherlands B.V., Amstelveen, The Netherlands)
and incubating overnight while shaking at 37 °C in medium
containing ampicillin (100 μg/ml) and kanamycin (25 μg/ml). The
next day, maxisorp wells were washed three times with PBS and
blocked with 4 % marvel in PBS. Phages were precipitated by
adding 2 % polyethylene glycol (PEG) and 250 mM NaCl for
30 min on ice. After spinning down and resuspending the pellet in
ice cold PBS, PEG precipitation was repeated twice. After
resuspension, phages were incubated in the blocked maxisorp wells
for 2 h at room temperature, while shaking. Non-specific phages
were removed by washing twenty times with PBS containing
0.05 % Tween, every fifth time shaking for 10 min. Bound phages
were eluted by trypsin digestion (1.0 mg/ml) for 20 min and
infection of an E.coli culture in the exponential phase of the growth
for 30 min after adding trypsin inhibitor. After infection, phages
were titrated, spotted on agar plates (containing 100 μg/ml
ampicillin and 2 % glucose) to calculate the number of bound
phages. Subsequently, the infections were grown overnight in 2TY
medium containing 100 μg/ml ampicillin and 2 % glucose, shaking
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at 37 °C. The next day, the overnight culture was used for phage
production. On the third day, a second round of selections was
performed by incubating output phages from the first round of
selections in wells coated with a concentration range of 0.01 to
1.00 μg recombinant CAIX.
Nanobody Production and Purification
Nanobodies were re-cloned from the pUR8100 phagemid vector
into the pQVQ72 expression vector (kindly provided by QVQ BV,
Utrecht, The Netherlands), which introduces a C-terminal cysteine,
flanked by a Flag-tag to enable site-directed conjugation of
IRDye800CW-Maleimide (LI-COR Biosciences, Lincoln, NE)
(see electronic supplementary material (ESM) for more details).
Generation of Family-Specific Phage sub-Library
(BFamily Approach^)
Based on the sequence of two anti-CAIX nanobodies, two family-
specific sub-libraries were made following the procedure previous-
ly described [28], with a few modifications. A unique degenerate
reverse primer extending into the entire CDR3 loop region was
designed and used in conjunction with the plasmid-based primer
(M13 rev) to PCR VHH gene fragments with the same CDR3
present in the library. Amplification was carried out with Phusion
High-Fidelity DNA Polymerase (Thermo Fisher Scientific,
Landsmeer, The Netherlands), and a 350-bp band was excised
after separation on an agarose gel. Following restriction enzyme
digestion with BstEII and SfiI and gel purification, the digested
DNA fragments were ligated into the phagemid vector pUR8100
for display on filamentous bacteriophage and transferred to E. coli
TG1 competent cells by electroporation. The resulting two family
libraries were used for phage display selections as described above.
Conjugation of IRDye800CW to CAIX
Nanobodies
Before IRDye800CW labeling, nanobodies were reduced by adding
70-fold molar excess of Tris (2-CarboxyEthyl) Phosphine hydro-
chloride (TCEP). IRDye800CW-Maleimide (further referred to as
IR; LI-COR) was conjugated to nanobodies following manufacturer
recommendations (see ESM for more details).
Results
Immunization, Library Construction, Phage
Display Selections, and Screening
To enable llama immunization with cells showing sufficient
levels of CAIX expression, we first evaluated CAIX
expression levels of several cell lines cultured in vitro under
normoxic and hypoxic conditions [29]. Cells were grown for
24 h at 1 % O2, and the CAIX expression was analyzed by
cell-based enzyme-linked immunosorbent assay (ELISA).
HeLa cells showed the highest CAIX upregulation and no
CAIX expression was observed in the control cell line
(Fig. 1a). As described in the ESM, two llamas were
immunized with hypoxic HeLa cells, which express native
CAIX, and pre- and post-immunization sera were used to
follow the development of an immune response against
CAIX. A VHH phagemid library was prepared as described
previously [30], and using this library, various phage display
selections were performed using either directly coated
recombinant CAIX, captured recombinant CAIX or hypoxic
HeLa cells with or without specific elution using anti-CAIX
mAb (Fig. 1b). After two rounds of biopanning, the binding
of nanobodies provided with a his- and myc-tag, was
analyzed in vitro using CAIX-overexpressing or CAIX
Fig. 1 Hypoxic HeLa cells can be used for generation of a
hypoxia-specific phage library. a Indicated cells were grown
under normoxic (21 % O2) (red) and hypoxic (1 % O2) (blue)
conditions for 24 h, and CAIX levels were determined by a
cell-based ELISA as described in Materials and Methods in
the ESM. b Workflow of phage display selections: 1. Llamas
are immunized with hypoxic HeLa cells; 2. During the
immune response peripheral B-lymphocytes generate CAIX-
specific heavy chain-only antibodies; 3. peripheral B-
lymphocytes are isolated and RNA is extracted. After reverse
transcriptase PCR, antibody specific DNA is ligated into a
phagemid vector; 4. Phages expressing nanobodies at their
surface are produced in E. coli bacteria; 5. Two rounds of
phage display selections are performed in a 96-wells format
coated with recombinant CAIX.
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negative MCF10DCIS cells grown under normoxic con-
ditions [11]. From these screenings, two CAIX-specific
nanobodies were isolated, indicated as CAIX1 and CAIX4.
Nanobody Characterization and Generation of a
CAIX Family-Specific Phage Library
To verify the specificity of the CAIX1 and CAIX4 nano-
bodies, immunofluorescence studies were performed using
co-cultures of CAIX-overexpressing (DCIS + CAIX) and
CAIX negative (DCIS) MCF10DCIS cells. Cells were
incubated with CAIX1 or CAIX4 nanobodies, which were
detected with antibodies directed against VHHs (Fig. 2a,
green). Expression of FLAG-CAIX was verified using anti-
FLAG antibodies (Fig. 2a, red). The overlay shows that both
nanobodies are binding specifically to the DCIS + CAIX
cells. CAIX negative cells did not show any nanobody
binding (Fig. 2a, arrows). Subsequently, binding experi-
ments were performed (as described in the ESM) to
determine apparent affinities (KD) of the unconjugated
nanobodies for CAIX, which were 11 nM for CAIX1 and
45 nM for CAIX4 (Fig. 2b).
To obtain anti-CAIX nanobodies with higher affinities, a
new second-generation family-specific library was made as
previously described by Koh et al. [28]. Primers were
designed based on the N-terminal framework sequence and
on the CDR3 sequence of CAIX1 or 4, and a PCR was
performed using the original library as template (Fig. 2c). A
novel CAIX library was constructed by ligating the PCR
products into a phagemid vector. With this novel CAIX
library, phage display selections were performed using
recombinant CAIX, resulting in the isolation of three
additional anti-CAIX nanobodies indicated as C5, B9 (both
based on CAIX1), and E4 (based on CAIX4). Affinity
determination of the C5 and B9 nanobodies showed an
improvement in affinity from the original 11 nM (CAIX1) to
6 nM (C5) and 7 nM (B9). Affinity also improved with the
CAIX4-based family approach: from 45 nM for the CAIX4
nanobody to 2 nM, which was the affinity of the novel anti-
CAIX nanobody E4.
Characterization of IR-Conjugated CAIX Nano-
bodies
The four CAIX-specific nanobodies were conjugated site-
directedly via a C-terminal cysteine residue (as described
previously [9]), as random conjugation could considerably
reduce the affinity of the nanobodies. After conjugation with
maleimide-IRDye800CW, the degree of labeling was ap-
proximately 0.6 for all nanobodies. The binding affinity of
the nanobodies (KD) was determined using DCIS + CAIX
cells. In pilot studies with CAIX negative MCF10DCIS,
signals did not exceed background (data not shown). The
binding affinities were 19 nM (CAIX1-IR), 17 nM (C5-IR),
13 nM (B9-IR), and 8 nM (E4-IR) (Fig. 2d). Despite the
site-directed dye conjugation, this labeling procedure re-
duced the binding affinity and had even a detrimental effect
on the affinity of CAIX4-IR. The Bmax of all nanobodies was
comparable to CAIX1-IR (~80 a.u.), except for E4-IR,
which had a lower Bmax (~40 a.u.; Fig. 2d). We selected B9-
IR as lead nanobody for further in vivo studies because of
the best binding affinity (13 nM) in combination with a high
Bmax.
The specificity of the B9 nanobody for CAIX was
confirmed in two ways. First, we compared immunofluores-
cence of DCIS cells with the same cells ectopically
expressing CAIX (DCIS + CAIX). A clear difference was
observed, i.e., more binding was observed for the cell line
with the highest expression of CAIX (Fig. 1S).
Subsequently, we incubated DCIS + CAIX cells with a
mixture of 2.5 nM B9 with 500 molar excess of the human
recombinant CAIX ectodomain. No immunofluorescence
was observed, demonstrating that the binding of the B9
nanobody was competed off by the presence of the CAIX
ectodomain (Fig. 1S).
In Vivo and Ex Vivo Optical Imaging
The feasibility of optical imaging with the B9-IR CAIX-
specific nanobody was tested in a preclinical setting, with
SCID/Beige mice that were orthotopically transplanted with
MCF10DCIS cells expressing CAIX peri-necrotically
(‘DCIS’ tumors) and MCF10DCIS cells stably expressing
exogenous CAIX (BDCIS+CAIX^ tumors). A non-relevant
R2 nanobody was used as a negative control [9, 24]. Upon
development of palpable tumors, mice were injected in the
tail vein with 50 μg of the indicated nanobodies. Fluorescent
probe distribution was visualized at several time points up to
48 h post injection using an imaging camera developed and
approved for clinical use [31]. Already 2–3 h p.i., we could
delineate both the DCIS+CAIX and DCIS tumors from the
background non-invasively (Fig. 3a) and invasively
(Fig. 3b, c).
TNRs were calculated by dividing the fluorescent signal
from the tumor by the signal from the hind leg for each time
point up to 48 h. The mean in vivo DCIS+CAIX TNR
increased in the first hour, until a plateau level was reached,
which persisted for 8 h (Fig. 4a). Two hours after probe
administration, a mean in vivo DCIS+CAIX TNR of 4.3±0.6
(standard error of the mean (SEM), n=8) was observed. At
2 h post injection, the mean DCIS TNR in mice injected
with B9-IR was 1.8±0.1 (n=8), and mice injected with the
R2-IR non-relevant control nanobody showed a TNR of 1.4
±0.2 (n=4; p=0.07; Fig. 4b). The TNR of 1.8 was sufficient
to detect DCIS tumors with a diameter starting from 2 mm
(data not shown).
After these studies, mice were sacrificed, and the skin
was removed to enable ex vivo tumor imaging, simulating
the surgical setting. The mean ex vivo or Bintra-operative^
TNR of CAIX-overexpressing tumors 3 h post injection was
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5.2±0.9, slightly higher than in the in vivo setting (Fig. 4c).
The mean TNR of the DCIS tumors from mice injected with
B9-IR or R2-IR was 2.1±0.2 and 1.3±0.1, respectively
(p=0.04). The maximum intra-operative TNR of the DCIS
tumors obtained from mice injected with B9-IR or R2-IR
was 2.7 and 1.5, respectively. These results show that
DCIS+CAIX tumors can be detected both in vivo as well as
under ex vivo conditions.
Biodistribution
To quantify fluorescent probe signals from tumors and organs,
we performed a biodistribution study, circumventing effects of
scattering and quenching of the fluorescent signal [9, 32]. To
determine the biodistribution of B9-IR and R2-IR, organs and
tumors of nine mice were excised, weighted, and after
processing, their fluorescent signals were determined. In the
Fig. 2 CAIX1 is a high-affinity CAIX-specific nanobody, and CAIX1 DNA can serve as template for the family approach. a Co-
cultures of CAIX-FLAG expressing and CAIX negative cells were incubated with either CAIX1 or CAIX4 nanobody. Nuclei were
stained with DAPI (blue). Bound nanobodies were detected with Alexa-488 (green) and CAIX-FLAGwith Alexa-555 (red). The overlay
is shown in the right panels. Arrows indicate cells without CAIX expression. Scale bar: 10 μm.bDCIS+CAIX cells were incubatedwith
a dilution series of CAIX1 and CAIX4 nanobodies, which were detected using anti-VHH antibodies and peroxidase conjugated
secondary antibodies. The y-axis shows intensity of peroxidase substrate. c Library DNA is used as template in a PCR reaction with
family-specific reverse primers covering CDR3. The PCR product is ligated in a phagemid vector resulting in a family-specific phage
library. d DCIS+CAIX cells were incubated with a dilution series of nanobody conjugated to IRDye800CW: CAIX1 (left, gray), CAIX4
(right, gray) and the nanobodies derived from the family-specific library (black) based on CDR3 of either CAIX1 (C5 and B9) or CAIX4
(E4). The y-axis shows fluorescence intensity measured by the Odyssey system.
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DCIS+CAIX tumors 14.0±1.1 % of the injected dose of B9-IR
per gram tissue (ID/g) was present, and 4.6±0.8 %ID/g was
found in DCIS tumors, which was significantly higher than for
muscle or blood (0.2±0.1 and 0.6±0.2 %ID/g, respectively). In
the DCIS+CAIX tumor 1.9±0.5 %ID/g of the injected dose of
the R2-IR negative control nanobody was found, which differs
significantly from the B9 accumulation (p=0.01). The difference
between B9-IR and R2-IR for the DCIS tumor was not
significant (4.6±0.8 vs 2.0±0.2 %ID/g; p=0.2). Compared to
other organs, kidney uptake of the nanobodies was high, which
is due to kidney retention of the nanobodies, confirming the
biodistribution assays performed previously [9, 24] (Fig. 4d).
Imaging of Tumor Sections and
Immunohistochemistry
To investigate the binding of the anti-CAIX nanobodies to
hypoxic areas in the tumors, tumors were collected 3 h post
injection from mice injected with either B9-IR or R2-IR.
Tumors were formalin fixed, paraffin embedded, and
sections of the tumors were scanned with the Odyssey
imaging system to detect IR fluorescence. In the DCIS
tumors the anti-CAIX nanobody was clearly visible in the
perinecrotic areas surrounding the necrotic area of the
xenografts (Fig. 5a–d). DCIS+CAIX tumors showed a
homogeneous fluorescent staining of the xenografts
(Fig. 5e–g). B9-IR staining of the xenografts co-localized
with the intra-tumoral membraneous distribution of CAIX,
which was detected by immunohistochemistry using an anti-
CAIX antibody. The non-relevant control nanobody R2-IR
showed no uptake in tumor tissue (Fig. 5h–j). However,
fluorescent sections together with H&E stained sections
demonstrated the limited uptake of R2-IR in surrounding
mouse mammary gland tissue.
Discussion
For rapid molecular imaging of (pre-invasive) tumors in
general and breast cancer in particular, targeting of tumor
biomarkers using optical tracers or radiotracers is essential
for contrast enhancement. Valid tumor markers are plasma
membrane proteins that are specifically expressed in the
tumor and not in surrounding tissue, such as HER2 [9].
However, HER2 is only expressed in 15–20 % of breast
cancers; thus, the drawback of some of these markers is their
expression in only a small percentage of breast cancers. As a
more general marker for cancer, we selected CAIX, which is
substantially upregulated under hypoxic conditions at the
cell surface of many tumor types. Others have evaluated
both CAIX inhibitors and CAIX antibodies for in vivo tumor
imaging [11, 21, 22].
A novel and versatile targeting platform are nanobodies.
In the current study, we have generated hypoxia-specific
nanobodies that specifically bind to the hypoxia marker
CAIX. These anti-CAIX nanobodies were selected by a
phage display family approach using an immune sub-library
in order to select for nanobodies against CAIX with the
highest affinity possible. The success of this approach was
demonstrated by the fact that affinities of these nanobodies
were better than the affinities from nanobodies selected from
the original immune library. Recently, a different study
reported the selection of nanobodies binding to CAIX,
which was shown to have a binding affinity (KD) of 23 μM
[33]. As previously shown, nanobodies with an affinity of
1 μM did not sufficiently accumulate in the tumor,
emphasizing the need for high-affinity binders [9, 34]. In
this context, we have shown that the binding affinity can
seriously drop after the conjugation of the nanobody to the
tracer, in this case the fluorophore IRDye800CW. As this
Fig. 3 Detection of hypoxic pre-invasive breast tumors
in vivo and intra-operatively using the B9-IR nanobody. a
DCIS+CAIX and DCIS xenografts were imaged at several
time points post injection of 50 μg B9-IR nanobody or 50 μg
R2-IR. Tumors were held between tweezers. b Intra-
operative imaging of DCIS and DCIS+CAIX tumors, 3 h post
injection of B9-IR. c Schematic overview of mammary glands
(2–5) and tumors as seen intra-operatively. DCIS+CAIX tumor
indicated as BCAIX^ in dark gray.
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was also the case for the selected anti-CAIX nanobodies, the
dye was conjugated via a C-terminal cysteine. The B9-IR
nanobody was finally selected as lead product because of the
excellent binding properties (KD=13 nM) in combination
with high Bmax.
An orthotopic xenograft mouse model was used to
validate tumor imaging using anti-CAIX nanobodies. This
mouse model resembles the tumor and tumor micro-
environment of human breast cancer more closely than
subcutaneous tumor models. The MCF10DCIS cells express
little CAIX when grown at normoxic conditions. However,
in vivo, these tumor cores can become necrotic and CAIX
expression is induced peri-necrotically [11]. Essential for
successful translation of optical molecular tracers to a
clinically useful tool is a high-imaging contrast. Optimal
contrast is established by two factors: high probe accumu-
lation in the tumor in combination with a rapid clearance of
the non-bound probe from the body resulting in low
background signals. As a direct measure of contrast, we
determined the TNR, both in vivo and in an intra-operative
setting. Already 1 h after tracer administration, the mean
TNR for DCIS+CAIX was ~4.6, which remained stable for
the next 8 h. The differences in TNR between DCIS+CAIX
and DCIS tumors confirm that, as could be expected, besides
the affinity and specificity of the probe, also the expression
levels of the molecular target are important to achieve a
sufficient TNR. Although CAIX expression is the result of a
cellular response to a physiological condition which does not
occur in all tumor cells within a tumor, our in vivo studies
show that it is sufficient to render tumors fluorescent and
detectable with the clinical camera.
The difference between the in vivo and ex vivo TNR can
be explained by the limited penetration of light through the
skin and subcutaneous tissue, which underscores the notion
that optical imaging might especially be suitable for image-
guided surgery. As negative control nanobody, we used the
non-relevant nanobody R2-IR, which was raised against the
molecule RR6 [35]. Our biodistribution studies showed that
~1.9 % of the injected dose of the R2-IR nanobody was
found in the tumors, which was clearly higher than found in
previous studies where we showed a TNR of approximately
1 [9]. The immunohistochemistry data suggest that this
might be caused by a specific binding of this nanobody to
vascular tissue surrounding the tumor (Fig. 5j).
An important advantage of the application of nanobodies
as targeted probes in optical molecular imaging is the short
time interval between probe injection and imaging proce-
dures. The rapid clearance can be related to the detection of
B9-IR in the kidneys, as previously described for nano-
bodies targeting EGFR or HER2 [9, 24]. The previously
Fig. 4 Optimal imaging with B9-IR nanobody 2 h post injection. a Mean TNR of CAIX-overexpressing tumors (DCIS+CAIX,
n=10), and DCIS tumors (n=10) determined during the first 8-h post injection of B9-IR nanobody. Error bars represent SEM. b
Mice xenografted with DCIS tumors were injected with 50 μl B9-IR (10 mice) or R2-IR (4 mice) non-relevant control nanobody,
mean TNR values were determined at indicated time points. c DCIS+CAIX (7 mice) and DCIS (7 mice) tumors after injection with
50 μg B9-IR, and DCIS+CAIX tumors (n=6) after injection with R2-IR non-relevant control nanobody. Single values of intra-
operative TNRs were determined 3 h post injection. Bar represents the mean (*p=0.04). d For a biodistribution assay, mice (n=9)
were injected with B9-IR or R2-IR non-relevant control nanobody. Tumors and organs were collected 3 h post injection. Error
bars represent SEMs.
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described hypoxia marker HS680 (KD=8.3 nM; MW 1372)
was only rendering tumors visible 96 h post injection [22].
As a direct result of the rapid pharmacokinetics of nano-
bodies, these probes offer a reduction in logistical burden
when applied in a clinical setting, as probe administration
and diagnostic or surgical procedures can be performed
within a few hours. Further improvement of this system can
be expected by the conjugation of several IRDye800CW
molecules to the same nanobody, which will require new
conjugation strategies.
A promising novel application of molecular imaging in
the field of pathology was previously indicated as
Bmolecular fluorescence pathology^ [11]. Analysis of tumor
sections is normally done with conventional IHC. However,
our strategy allows direct analysis of tumors’ molecular
status on tissue sections using fluorescence microscopy
(Fig. 5). The CAIX-specific nanobody accumulated very
well in the perinecrotic areas of the DCIS tumor, where high
CAIX expression was confirmed by IHC while low
expression was found in surrounding normoxic tumor tissue.
As with fluorescence microscopy, various NIR-dyes can be
detected at the same time; the problem of heterogenous
tumor binding of CAIX-specific nanobodies can be solved
by co-injection of two or multiple probes, with specificities
for other tumor markers. Also, dual labeling would allow
molecular characterization of tumors and could be advan-
tageous for a better delineation of the tumor, which is
essential for imaging of tumor margins. Moreover, we
anticipate the application of nanobodies in other imaging
modalities such as immuno-PET. The rapid clearance of
radiolabeled nanobodies allows for application of isotopes
with short half-life (Ga-68, half-life 68 min), which will
contribute to lower exposure of the patient to radioactive
tracers [26, 36]. With this modality, whole body imaging
becomes possible, which is very interesting for detection of
distant metastases during the course of the breast cancer
disease.
Conclusions
We have produced a novel fluorescent CAIX-specific nanobody
and demonstrated the application of this probe preclinically in
Fig. 5 B9-IR binds to perinecrotic area in DCIS tumors. a–d DCIS tumor from a mouse injected with B9-IR nanobody, 3 h post
injection. e–g DCIS+CAIX tumor from a mouse injected with B9-IR. h-j. DCIS tumor from a mouse injected with R2-IR (non-
relevant control nanobody). a Fluorescence scan of DCIS tumor. b CAIX-IHC. c Magnification of perinecrotic area. d H&E
staining of tumor section. e Fluorescence scan of DCIS+CAIX tumor. f Magnification of CAIX-IHC. g H&E staining of tumor
section. h Fluorescence scan of DCIS tumor with central necrosis. i CAIX-IHC. j magnification of CAIX-IHC (*indicates necrotic
area).
542 A.S.A. van Brussel et al.: Hypoxia-Targeting Nanobodies for Breast Cancer Imaging
optical molecular imaging of hypoxic pre-invasive breast cancer
before and during surgery. A major advantage of using
nanobodies is the high contrast already obtained 2 h after probe
administration. Because of these pharmacokinetics, probe
injection and surgical procedures can be performed on the same
day. Furthermore, the stability of the conjugate allows for
Bmolecular fluorescence pathology^, which might result in
better contrast than conventional CAIX-IHC at the pathology
department. Molecular fluorescence pathology might be useful
for patient-tailored therapeutic decision making in the future.
Because of the potentially broad applicability of this probe for
many different (hypoxic) tumors, we aim for rapid translation of
B9-IR toward clinical studies.
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